Jefferies starts Merck KGaA at Hold, sees limited upside

Jefferies initiated coverage of Merck KGaA with a Hold rating and a €129 price target, saying the stock already reflects its key growth opportunities and near-term challenges. The firm sees Life Science as the main growth engine, expects Electronics to benefit from AI-driven semiconductor demand, and forecasts 4.7% annual revenue growth from 2025 to 2029 with adjusted EBITDA margins rising to about 30%. Despite constructive long-term fundamentals, Jefferies said upside looks limited unless execution improves in Life Science, rare diseases, or semiconductors.

Analysis

The main takeaway is not the neutral rating itself, but that the market already assigns Merck a fairly efficient multiple for a business with three very different option values: cyclical bioprocessing recovery, structural semiconductor content growth, and an embedded healthcare turnaround. That combination usually reduces valuation dispersion, because any one upside stream is offset by the others’ execution risk. In other words, the stock is less a clean growth compounder and more a sum-of-parts that can only rerate if two engines accelerate at once.

The underappreciated second-order issue is timing mismatch. Life science recovery is likely a 2-4 quarter story tied to bioprocessing and consumables normalization, while semiconductor materials is a multi-year AI capex call that can de-rate quickly if advanced-node spending pauses. That leaves the shares vulnerable to “good but not good enough” quarters: even modest revenue beats may not lift the multiple unless management can show sustained margin expansion and a clearer inflection in rare disease contribution.

Contrarianly, the consensus may be too comfortable treating electronics as a durable AI beneficiary. Specialty materials suppliers often see order pull-forward ahead of node transitions, followed by digestion periods that can last several quarters; that creates headline growth but weak incremental earnings power. If AI capex broadens beyond a few hyperscalers, Merck benefits, but if spending stays concentrated, the market may overestimate duration and underestimate lumpiness.

Catalyst-wise, the next 6-12 months matter more for sentiment than the medium-term model. A stronger biologics rebound plus evidence of operating leverage in Life Science would be the cleanest rerating trigger; absent that, the shares likely remain rangebound and behave more like a quality industrial with biotech exposure than a genuine growth re-rate candidate.

Key Decisions for Investors

• Stay neutral/market-weight Merck KGaA over the next 3-6 months; the risk/reward is skewed toward time decay unless Life Science data meaningfully inflects.
• Pair trade: long a higher-beta life science supplier with clearer recovery torque, short Merck KGaA, to isolate the rebound in biologics demand versus Merck’s already-embedded valuation.
• Use any 5-8% post-earnings pullback to sell cash-secured puts or initiate a small tactical long only if management guides to sustained Life Science acceleration; otherwise expect the stock to mean-revert.
• For a 6-12 month view, consider a call spread only if semiconductor materials orders show evidence of broadening beyond AI headline demand; absent that, upside is capped and theta is unfavorable.